Saluda Medical, Inc. (ASX:SLD)

Saluda Medical Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023
Revenue	70.36	51.68	22.23
Revenue Growth (YoY)	36.13%	132.45%	-
Cost of Revenue	37.6	28.57	18.2
Gross Profit	32.76	23.11	4.04
Selling, General & Admin	115.35	93.05	68.15
Research & Development	35.46	29.2	28.11
Operating Expenses	150.81	122.25	96.26
Operating Income	-118.05	-99.14	-92.22
Interest Expense	-27.24	-5	-4.67
Interest & Investment Income	2.01	5.47	3.21
Currency Exchange Gain (Loss)	1.65	0.11	1.43
Other Non Operating Income (Expenses)	-7.15	1	0.7
Pretax Income	-148.77	-97.55	-91.55
Income Tax Expense	0.53	0.27	0.61
Net Income	-149.3	-97.83	-92.16
Net Income to Common	-149.3	-97.83	-92.16
Shares Outstanding (Basic)	167	167	167
Shares Outstanding (Diluted)	167	167	167
Shares Change (YoY)	0.13%	0.06%	-
EPS (Basic)	-0.89	-0.58	-0.55
EPS (Diluted)	-0.89	-0.58	-0.55
Free Cash Flow	-119.51	-94.4	-88.03
Free Cash Flow Per Share	-0.71	-0.56	-0.53
Gross Margin	46.56%	44.72%	18.17%
Operating Margin	-167.79%	-191.82%	-414.78%
Profit Margin	-212.21%	-189.29%	-414.52%
Free Cash Flow Margin	-169.87%	-182.66%	-395.93%
EBITDA	-116.4	-97.25	-90.94
EBITDA Margin	-165.45%	-188.17%	-
D&A For EBITDA	1.65	1.89	1.29
EBIT	-118.05	-99.14	-92.22
EBIT Margin	-167.79%	-191.82%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.